BioSepra and Sepracor countersue PerSeptive Biosystems:
This article was originally published in Clinica
Executive Summary
BioSepra and Sepracor have filed a claim in a US district court against PerSeptive Biosystems, alleging unfair competition in connection with BioSepra's patented HyperD chromatography media. The suit, filed in the Massachusetts District Court, claims PerSeptive used lawsuits alleging HyperD infringed its patents related to the company's "perfusion chromatography" to compete unfairly with BioSepra (see Clinica No 641, p 11). "The unfair competition claim will remind PerSeptive that the use of lawsuits as a marketing tool is inappropriate," says BioSepra's president, Jean-Marie Vogel.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.